A Novel DNA-Based Vaccine Methodology for AIDS
Abstract
A novel DNA-based vaccine strategy, employing a particle delivery device to administer gold beads directly into the cells of the epidermis was tested for the ability to induce humoral and cellular immune responses to the AIDS virus and to generate preclinical data for future human clinical trials. SIV DNA vaccine induction of CTL correlated with significant virus load reduction of up to 10,000-fold when compared to control monkeys following challenge with a pathogenic, heterologous SIV. DNA administration to either the skin or mucosal tissue induced low levels of mucosal antigen-specific CTL and antibody responses. Following intrarectal challenge with SIV, virus loads were below the limit of detection in 4 of 7 DNA vaccinated monkeys and in 1 of 7 control animals. Studies to evaluate a CTL epitope-based DNA vaccine demonstrated the induction of high frequency CD8+ T cell responses in rhesus macaques. Evaluation of strategies to augment or modulate immune responses induced by particle-mediated DNA immunization demonstrated that co-administration of DNA with adjuvants resulted in substantial augmentation of both antibody and CTL.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 1999
- Accession Number
- ADB252231
Entities
People
- Dexiang Chen